Project Grant R01AI180302
Award Date 8/1/25
Completion Date 7/31/29
Dollars Obligated $1.8M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), awarded a $490,093 Project Grant to the University of Maryland, College Park on April 10, 2025. The funding supports the development of a rapid, inexpensive microfluidic technology to isolate bacteria directly from whole blood, identify pathogens, and evaluate their antibiotic response within 75 minutes. This will enable clinicians to move...
- This $420,553 federal Project Grant award was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant aims to develop a single-cell technique that will measure the translation rate and transcriptome of thousands of individual bacterial cells, with a focus on understanding antibiotic tolerance in Staphylococcus aureus during chronic infections. The research will explore the heterogeneity in...
- This $424,265 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on August 7, 2025 supports the development of an integrated "DIMS-RAMAN" platform to rapidly isolate and analyze bacterial cells from blood samples within 1-2 hours. The proposed system combines a novel density-shift immunocapture separation (DIMS) technique to directly separate microbial cells from whole blood, with Raman...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $125,973 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of Michigan. The grant, awarded on February 3, 2025, aims to identify patient and bacterial factors associated with the emergence and spread of resistance to two novel beta-lactam/beta-lactamase inhibitor antibiotic therapies: meropenem-vaborbactam and imipenem-relebactam. The researchers...
- This $392,634 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel nanoimmunotherapeutic approach to combat multidrug-resistant (MDR) bacterial infections. The project aims to design, fabricate, and optimize a red blood cell membrane-coated, hemoglobin-encapsulating nanoparticle (RHNP) that can sensitize bacteria to host oxidant killing while...
- This federal Project Grant award of $3,055,197.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective of the project is to evaluate the potential impact of rapid detection of carbapenemase-producing organisms (CPOs) using a form-factor optimized phenotypic test paired with machine learning algorithms. The goal is to increase CPO detection, decrease time-to-identification of CPO...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $212,169 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to The Johns Hopkins University to advance mentorship at the Johns Hopkins Integrated Center for Combating Antimicrobial Resistant Bacteria. The project summary indicates the principal investigator has conducted pivotal research on antimicrobial resistant infections, leading to clinical guidelines, and has...
- This $1,378,102 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), to Health Research, Inc. at its Wadsworth Center Division. The grant supports research to develop the therapeutic potential of a mycobacteriophage lysin, LysB, as a broad-spectrum adjunct treatment for Mycobacterium abscessus (MAB) infections, which are life-threatening for people with certain...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), provides $190,768 to Tufts Medical Center to develop a rapid transcriptomic antimicrobial susceptibility testing (AST) assay for identifying susceptibility to clarithromycin and imipenem in Mycobacterium abscessus infections. The research aims to improve the identification of effective treatment options for...
- This $747,763 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to develop small molecule inhibitors of the LpxH enzyme as novel antibiotics for treating multidrug-resistant Enterobacterales infections, such as those caused by extended-spectrum beta-lactamase (ESBL)-producing and carbapenem-resistant Enterobacterales (CRE). The goal is to design and synthesize potent LpxH inhibitors with...